glp-1 obesity drug study august 2025 trends 2025: real-world data, patient outcomes & future therapies Weight Reduction with GLP-1 Agonists

Among the 12% of adults who have ever taken GLP-1 drugs, most report taking them, at least in part, to treat a chronic condition like diabetes or heart disease, with fewer saying they took them only to lose weight

For youths considering GLP-1s, the decision should be at the discretion of the physician, the adolescent patient and their caregiver, Ms

Albiglutide and cardiovascular outcomes in participants with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

In diabetes-related AD, GLP-1 promotes mitochondrial biogenesis and the antioxidant system by regulating the PGC-1a signaling pathway in vivo to directly reverse tau hyperphosphorylation

2016;11:e0165267

The success of tirzepatide has validated the multi-agonist approach, driving substantial research and development in this area